IFBH(06603.HK)悉數行使超額配股權、穩定價格行動及穩定價格期間結束
格隆匯7月25日丨IFBH(06603.HK)公告,公司宣佈,獨家整體協調人(爲其本身及代表國際包銷商)已於2025年7月25日(星期五)悉數行使招股章程所述的超額配股權,涉及合共6,250,000股股份("超額配發股份"),佔全球發售項下初步可供認購的發售股份總數的約15.0%。
公司宣佈,全球發售的穩定價格期間於2025年7月25日(星期五)(即提交香港公開發售申請的截止日期後第30日)結束。有關穩定價格經辦人中信里昂證券有限公司或其聯屬人士或代其行事的任何人士在穩定價格期間內進行的穩定價格行動的進一步資料載於本公告內。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.